Arcede Pharma AB operates as a drug development company. It develops drug candidates to treat chronic obstructive pulmonary disease and severe asthma. The company's drug candidates include RESP3000, RESP9000, and RESP1000. The company was founded on October 21, 2003 and is headquartered in Lund, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company